Suraksha Diagnostic Ltd. (SURAKSHA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 2.80K
• Price to Earnings (P/E): 49.4
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 1,175
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.80
• Shares Outstanding: 52,080,757
• 10 Day Avg. Volume: 4,418
• 30 Day Avg. Volume: 2,801
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹343.00
• Price Target Upside: 8.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: ₹343.00 ▲(8.63% Upside)

The overall score of 62.1 reflects robust financial performance and efficient cash flow management as the most significant strengths. However, technical signals and high valuation present cautionary factors that balance the positive aspects. Investors should consider the high P/E ratio and lack of dividend yield when evaluating the stock's investment potential.

Suraksha Diagnostic Ltd. Business Overview & Revenue Model

Company Description

Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwavering commitment to accuracy and service, resulted in steady growth and popularity. Within 3 years they could confidently open a second Center at Siliguri, in North Bengal, which remains the largest such facility in the region, and today serves not only to patients from North Bengal, but also neighbouring States and countries. Since then they have grown steadily across Bengal, Bihar, and Delhi NCR.

How the Company Makes Money

Suraksha Diagnostic Ltd. primarily generates revenue through the provision of diagnostic services. The company charges fees for the various tests and screenings it offers, such as blood tests, MRI scans, CT scans, and other specialized diagnostic procedures. Revenue is derived from a combination of direct payments from patients and reimbursements from insurance companies and healthcare providers. Additionally, Suraksha may have partnerships with hospitals and clinics to serve as their outsourced diagnostic service provider, which further contributes to its earnings. The company may also explore strategic partnerships with medical equipment manufacturers and software providers to enhance its service offerings and operational efficiency.

Suraksha Diagnostic Ltd. Financial Statement Overview

Summary

Suraksha Diagnostic Ltd. demonstrates robust financial performance with strong revenue growth, high profit margins, and efficient cash flow management. The balance sheet is solid with a balanced leverage position and strong equity base, although careful management of liabilities is advised.

Income Statement

Suraksha Diagnostic Ltd. has demonstrated strong revenue growth with a revenue increase of 15.24% from the previous year. The company maintains a high gross profit margin of 88.27% and a net profit margin of 12.62%, indicating strong profitability. Both EBIT and EBITDA margins are solid at 19.09% and 33.75%, respectively, reflecting effective cost management. The consistent growth in net income and EBIT also highlights operational efficiency and profitability.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.42, indicating a balanced leverage position. The return on equity (ROE) is robust at 15.07%, showcasing effective utilization of shareholders' equity. The equity ratio stands at 63.34%, signifying a strong equity base relative to total assets. However, a slight increase in total liabilities over the years suggests a need for careful management of financial obligations.

Cash Flow

Operating cash flow to net income ratio is healthy at 1.99, suggesting strong cash generation relative to net earnings. Free cash flow has grown by 35.12%, indicating improved cash management. The free cash flow to net income ratio of 0.67 reflects effective capital expenditure management, although there is room for further enhancement in cash flow generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.52B	2.19B	1.90B	2.23B
Gross Profit	2.23B	1.91B	1.63B	1.63B
EBITDA	850.88M	736.56M	474.79M	652.53M
Net Income	318.24M	236.26M	65.16M	208.24M
Balance Sheet
Total Assets	3.34B	3.00B	2.81B	2.76B
Cash, Cash Equivalents and Short-Term Investments	226.36M	515.96M	522.79M	412.89M
Total Debt	888.86M	904.76M	968.74M	997.95M
Total Liabilities	1.23B	1.21B	1.26B	1.30B
Stockholders Equity	2.11B	1.79B	1.56B	1.46B
Cash Flow
Free Cash Flow	213.35M	157.90M	309.29M	385.74M
Operating Cash Flow	633.59M	604.84M	440.96M	578.23M
Investing Cash Flow	-395.84M	-349.96M	-207.95M	-432.81M
Financing Cash Flow	-240.48M	-251.30M	-243.28M	-142.85M

Suraksha Diagnostic Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INDRAMEDCO	74 Outperform	43.44B	25.91	26.98%	0.95%	6.80%	21.31%
METROPOLIS	72 Outperform	110.56B	72.28	10.89%	―	12.86%	10.42%
LALPATHLAB	70 Outperform	291.40B	56.49	22.42%	0.69%	10.57%	34.11%
VIJAYA	68 Neutral	108.56B	72.27	17.98%	0.19%	22.34%	20.71%
KRSNAA	63 Neutral	27.24B	33.82	8.79%	0.33%	13.78%	32.21%
SURAKSHA	62 Neutral		49.41		―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%